Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification

被引:57
作者
Chevaliez, Stephane
Bouvier-Alias, Magali
Pawlotsky, Jean-Michel [1 ]
机构
[1] Univ Paris 12, Hop Henri Mondor, Dept Virol, French Natl Reference Ctr Viral Hepatitis BC & De, F-94010 Creteil, France
关键词
ALPHA-2B PLUS RIBAVIRIN; AMPLICOR HCV MONITOR; PEGINTERFERON ALPHA-2B; MULTICENTER EVALUATION; GENOTYPE-2; QUANTITATION; TECHNOLOGY; TESTS;
D O I
10.1128/JCM.01300-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Quantification of hepatitis C virus (HCV) RNA is essential for the everyday management of chronic hepatitis C therapy. "Real-time" PCR techniques are potentially more sensitive than classical PCR techniques, are not prone to carryover contamination, and have a consistently wider dynamic range of quantification. Thus, they are rapidly replacing other technologies for routine quantification of HCV RNA. We extensively evaluated the intrinsic characteristics and clinical performance of the m2000(sp)-m2000(rt) Abbott real-time PCR platform for HCV RNA quantification. The study shows that the m2000(sp)-m2000(rt) platform is sensitive, specific, and precise; that the results are reproducible; and that the platform has a broad dynamic range of quantification. When comparing HCV RNA levels measured in the same individuals with the m2000(sp)-m2000(rt) platform and the third-generation branched-DNA assay, a trend toward a modest overestimation of HCV RNA levels was observed in the m2000(sp)-m2000(rt) platform in all genotypes except genotype 5. The differences, however, were unlikely to have any impact in clinical practice. In conclusion, our study shows that the Abbott m2000 real-time PCR system for HCV RNA quantification is sensitive, specific, and precise; that the results are reproducible; and that the platform's broad dynamic range of quantification is well suited to HCV RNA monitoring in the clinical setting.
引用
收藏
页码:1726 / 1732
页数:7
相关论文
共 27 条
[1]   Performance of the new Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: Conversion to international units and comparison with the Roche COBAS amplicor HCV monitor, version 2.0, assay [J].
Beld, M ;
Sentjens, R ;
Rebers, S ;
Weegink, C ;
Weel, J ;
Sol, C ;
Boom, R .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (03) :788-793
[2]   Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin [J].
Berg, T ;
von Wagner, M ;
Nasser, S ;
Sarrazin, C ;
Heintges, T ;
Gerlach, T ;
Buggisch, P ;
Goeser, T ;
Rasenack, J ;
Pape, GR ;
Schmidt, WE ;
Kallinowski, B ;
Klinker, H ;
Spengler, U ;
Martus, P ;
Alshuth, U ;
Zeuzem, S .
GASTROENTEROLOGY, 2006, 130 (04) :1086-1097
[3]   Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin [J].
Bronowicki, Jean-Pierre ;
Ouzan, Denis ;
Asselah, Tarik ;
Desmorat, Herve ;
Zarski, Jean-Pierre ;
Foucher, Juliette ;
Bourliere, Marc ;
Renou, Christophe ;
Tran, Albert ;
Melin, Pascal ;
Hezode, Christophe ;
Chevalier, Michelle ;
Bouvier-Alias, Magali ;
Chevaliez, Stephane ;
Montestruc, Francois ;
Lonjon-Domanec, Isabelle ;
Pawlotsky, Jean-Michel .
GASTROENTEROLOGY, 2006, 131 (04) :1040-1048
[4]   Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method [J].
Chevaliez, Stephane ;
Bouvier-Alias, Magali ;
Brillet, Rozenn ;
Pawlotsky, Jean-Michel .
HEPATOLOGY, 2007, 46 (01) :22-31
[5]   The Cobas AmpliPrep-Cobas TaqMan Real-Time Polymerase Chain Reaction Assay Fails To Detect Hepatitis C Virus RNA in Highly Viremic Genotype 4 Clinical Samples [J].
Chevaliez, Stephane ;
Bouvier-Alias, Magali ;
Castera, Laurent ;
Pawlotsky, Jean-Michel .
HEPATOLOGY, 2009, 49 (04) :1397-1398
[6]   Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study [J].
Dalgard, O ;
Bjoro, K ;
Hellum, KB ;
Myrvang, B ;
Ritland, S ;
Skaug, K ;
Raknerud, N ;
Bell, H .
HEPATOLOGY, 2004, 40 (06) :1260-1265
[7]   Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C [J].
Davis, GL ;
Wong, JB ;
McHutchison, JG ;
Manns, MP ;
Harvey, J ;
Albrecht, J .
HEPATOLOGY, 2003, 38 (03) :645-652
[8]   Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow [J].
Elbeik, T ;
Markowitz, N ;
Nassos, P ;
Kumar, U ;
Beringer, S ;
Haller, B ;
Ng, V .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (07) :3120-3127
[9]   Multicenter evaluation of the performance characteristics of the Bayer VERSANT HCV RNA 3.0 assay (bDNA) [J].
Elbeik, T ;
Surtihadi, J ;
Destree, M ;
Gorlin, J ;
Holodniy, M ;
Jortani, SA ;
Kuramoto, K ;
Ng, V ;
Valdes, R ;
Valsamakis, A ;
Terrault, NA .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (02) :563-569
[10]   Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin [J].
Ferenci, P ;
Fried, MW ;
Shiffman, ML ;
Smith, CI ;
Marinos, G ;
Gonçales, FL ;
Häussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxì, A ;
Chaneac, M ;
Reddy, KR .
JOURNAL OF HEPATOLOGY, 2005, 43 (03) :425-433